Sponsor of the Day:
Jerkmate
https://resources.healthgrades.com/drugs/opdivo-side-effects
Opdivo (Nivolumab) Side Effects: What to Expect
Sep 24, 2025 - Opdivo (nivolumab) is a medication prescribed for several types of cancer, including melanoma. Learn about its common, mild, and serious side effects.
side effectsopdivonivolumabexpect
https://www.opdivo.com/
OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer. Read the indications, side effects, and more. Please see Indication and...
nivolumab
https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog/2016/fda-nivolumab-cabeza-cuello
FDA aprueba el nivolumab para cáncer de cabeza y cuello
Artículo del blog Temas y relatos acerca de la aprobación de la FDA del nivolumab para carcinoma escamoso recurrente o avanzado de cabeza y cuello.
aprueba elde cabezafdanivolumabpara
https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/nivolumab
Nivolumab (Opdivo®) | Macmillan Cancer Support
Nivolumab (Opdivo®) is a cancer drug. It is used to treat many different cancer types.
macmillan cancer supportnivolumab
https://www.oncologyeducation.com/infographics/relativity-047-4-year-update-nivolumab-relatlimab-in-advanced-melanoma/
RELATIVITY-047 4-Year Update: Nivolumab + Relatlimab in Advanced Melanoma - OncologyEducation
Feb 4, 2026 - Explore 4-year data from RELATIVITY-047. 52% OS rate for NIVO + RELA in 1L advanced melanoma. Download the clinical infographic for Canadian specialists.
4 yearadvanced melanomarelativity047update